Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies

Abstract

The increased incidence of colorectal and stomach cancers reported here should be regarded as tentative until supported by long-term data from a larger number of tamoxifen trials. Also, appropriate surveillance of cancer incidence is warranted for the protection of participants enrolled in current tamoxifen chemoprevention trials.